Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation

Nobuya Harayama · Shun-ichi Nihei · Keiji Nagata · Yasuki Isa · Kei Goto · Keiji Aibara · Masayuki Kamochi · Takeyoshi Sata

Received: 10 February 2013/Accepted: 10 December 2013/Published online: 5 January 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract

Purpose Nifekalant is a pure potassium channel blocker that has been used to treat ventricular tachyarrhythmias since 1999 in Japan. Intravenous amiodarone was approved later than nifekalant in Japan, and it is still unclear which of the two agents is superior. The aim of this study was to compare the efficacy of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest caused by shock-resistant ventricular fibrillation.

Methods From December 2005 to January 2011, ambulance services transported 283 out-of-hospital cardiopulmonary arrest patients to our hospital. Of these, 25 patients were treated with nifekalant or amiodarone in response to ventricular fibrillation that was resistant to two or more shocks. We undertook a retrospective analysis of these 25 patients.

Results We enrolled 20 men and 5 women with a mean age (± standard deviation) of 61.1 ± 16.4 years. All 25 patients were treated with tracheal intubation and intravenous epinephrine. Fourteen patients received nifekalant and 11 patients received amiodarone. The rates of return of spontaneous circulation (ROSC) (nifekalant, 5/14, versus amiodarone, 4/11; P = 0.97) and survival to discharge (nifekalant, 4/14, versus amiodarone, 2/11; P = 0.89) were not significantly different between the two groups. The time from nifekalant or amiodarone administration to ROSC was 6.0 ± 6.6 and 20.3 ± 10.0 min, respectively, which was significantly different (P < 0.05).

Conclusion In this small sample size study, nifekalant, compared with amiodarone, is equally effective for ROSC and survival to discharge after shock-resistant ventricular fibrillation and can achieve ROSC more quickly. Further prospective studies are needed to confirm our results.

Keywords Nifekalant · Amiodarone · Out-of-hospital cardiopulmonary arrest · Ventricular fibrillation · Cardiopulmonary resuscitation

Introduction

Ventricular fibrillation is one of the most common life-threatening tachyarrhythmias, especially among out-of-hospital cardiopulmonary arrest patients. Because of the increased availability of automated external defibrillators in public locations, the number of out-of-hospital cardiopulmonary arrest patients with ventricular fibrillation receiving pre-hospital direct current (DC) shocks is increasing, and the survival rate of these patients has improved [1–3]. Patients with shock-resistant ventricular fibrillation need additional antiarrhythmic drug therapy, but the best protocol for this has not yet been established.

The ARREST study showed that, in patients experiencing out-of-hospital cardiopulmonary arrest because of shock-resistant ventricular fibrillation, treatment with amiodarone resulted in a higher rate of survival to hospital admission compared with placebo [4]. Amiodarone is currently widely used for the treatment of shock-resistant ventricular fibrillation [5, 6].
In Japan, both amiodarone and nifekalant are used as intravenous class III antiarrhythmic drugs. Nifekalant is a pure potassium channel blocker with a pyrimidinedione structure that was developed in Japan and has been used for the treatment of life-threatening ventricular tachyarrhythmia since 1999 [7]. Because intravenous amiodarone was approved later than nifekalant in Japan, nifekalant has been widely used as a class III antiarrhythmic intravenous drug. Amiodarone has various effects on ion channels, receptors, sympathetic activity, and thyroid function [8, 9], but nifekalant is a pure potassium channel blocker, specifically blocking the rapid component of delayed rectifier potassium currents (I_{Kr}) without blocking sodium or calcium channels [10]. In terms of pharmacological properties, nifekalant seems to have some advantages for use in cardiopulmonary resuscitation compared with amiodarone as it does not have a negative inotropic effect [11, 12].

The ALIVE study showed that amiodarone treatment improved hospital survival rate compared with lidocaine treatment in patients with out-of-hospital cardiopulmonary arrest caused by shock-resistant ventricular fibrillation [13]. It has been reported that not only amiodarone but also nifekalant is superior to lidocaine for resuscitation of shock-resistant ventricular fibrillation [14–16], but it is still unclear which is superior, nifekalant or amiodarone. To clarify this issue, we performed a retrospective study to compare the efficacy of nifekalant versus amiodarone for the resuscitation of out-of-hospital cardiopulmonary arrest caused by shock-resistant ventricular fibrillation.

### Patients, materials, and methods

We performed a retrospective review of 283 consecutive out-of-hospital cardiopulmonary arrest patients transported to our hospital by ambulance from December 2005 to January 2011. Cardiopulmonary resuscitation (CPR) was performed according to the 2005 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiac Care Science with Treatment Recommendations (CoSTR) by the International Liaison Committee on Resuscitation (ILCOR), with a protocol of one shock followed by 2 min of chest compression [17]. All physicians who treated the patients were staff doctors working in critical care medicine. Of the 283 patients, 50 had ventricular fibrillation in the emergency room, including 25 with shock-resistant ventricular fibrillation (defined as ventricular fibrillation resistant to two or more shocks in the emergency room). The 25 patients with shock-resistant ventricular fibrillation were enrolled in this study. All 25 patients were treated with tracheal intubation and intravenous epinephrine (1 mg every 3–5 min) before antiarrhythmic drug administration. The physicians treating the patient decided which class III antiarrhythmic drug to use (nifekalant or amiodarone) and the dosage. The class III antiarrhythmic drug was administered by slow intravenous injection within 1 min. The treating physicians also made decisions regarding additional treatments, including the use of extracorporeal life support (ECLS) for the patients who could not obtain return of spontaneous circulation (ROSC) after class III antiarrhythmic drug administration. We used ECLS according to the decision of physicians at the scene of CPR, based on the patient’s age, cause of cardiopulmonary arrest, presence of collapse witness, and bystander CPR. Survivors with ROSC underwent hypothermia therapy in the intensive care unit (ICU).

We compared the nifekalant and amiodarone groups in terms of (1) age, (2) gender, (3) causes of cardiopulmonary arrest, (4) rate of witnessed collapse, (5) rate of bystander CPR, (6) mean time from emergency call to paramedic arrival at the patient’s side, (7) mean time from paramedic arrival at the patient’s side to hospital arrival, (8) number of DC shocks before antiarrhythmic drug use, (9) total

### Table 1 Clinical characteristics of patients with out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation treated with nifekalant or amiodarone

|                         | Nifekalant group (n = 14) | Amiodarone group (n = 11) | P value |
|-------------------------|---------------------------|---------------------------|---------|
| Male                    | 78.6 % (11/14)            | 81.9 % (9/11)             | 0.84    |
| Age (years)             | 57.2 ± 16.8               | 66.0 ± 15.3               | 0.19    |
| Causes of CPA           |                           |                           |         |
| IHD                     | 71.5 % (10/14)            | 72.7 % (8/11)             | 0.71    |
| Cardiomyopathy          | 21.4 % (3/14)             | 9.1 % (1/11)              | 0.40    |
| Trauma                  | 7.1 % (1/14)              | 18.2 % (2/11)             | 0.64    |
| Presence of collapse witness | 50.0 % (7/14)       | 63.6 % (7/11)             | 0.50    |
| Presence of bystander CPR | 57.1 % (8/14)            | 45.5 % (5/11)             | 0.86    |
| Time interval (min)     |                           |                           |         |
| Emergency call–arrival of paramedics at the scene of CPA | 8.3 ± 3.0 | 8.0 ± 4.0 | 0.84 |
| Arrival of paramedics at the scene of CPA–hospital arrival | 15.1 ± 4.4 | 14.2 ± 3.3 | 0.55 |
| Hospital arrival–antiarrhythmic drug use | 14.5 ± 7.2 | 16.1 ± 7.1 | 0.59 |
| Number of DC shocks before antiarrhythmic drug use (times) | 3.1 ± 1.2 | 3.1 ± 0.9 | 0.91 |
| Dose of epinephrine before antiarrhythmic drug use (mg) | 2.6 ± 1.4 | 2.9 ± 1.9 | 0.69 |

Values are given as mean ± SD

CPR cardiopulmonary arrest, DC direct current, ICU intensive care unit, IHD ischemic heart disease, SD standard deviation
epinephrine dose, and (10) mean time from hospital arrival to class III antiarrhythmic drug administration.

To evaluate the efficacy of nifekalant versus amiodarone, we also compared the groups in terms of rate of ROSC, rate of survival to hospital discharge, mean time from the initiation of the drug administration to ROSC, number of DC shocks after antiarrhythmic drug use, and neurological outcome at hospital discharge as estimated using the Glasgow Outcome Scale (GOS) [18]. Statistical analyses were done with StatMate III for Macintosh (ATMS, Tokyo, Japan).

All parameters are described as mean ± standard deviation (SD). Statistical analyses were performed using the chi-square test and Student’s unpaired t test. A P value of <0.05 was considered statistically significant.

This study was carried out in accord with the principles of the Declaration of Helsinki and was approved by our University Ethics committee. The ethics committee does not require informed consent for retrospective studies such as this study.

Results

A total of 25 patients with shock-resistant ventricular fibrillation were enrolled in this study. Of these patients, 20 were male and 5 were female, with a mean age (±SD) of 61.1 ± 16.4 years. The initial class III antiarrhythmic drug administered was nifekalant in 14 patients and amiodarone in 11 patients. There were no significant differences in the clinical characteristics of patients in the nifekalant and amiodarone groups (Table 1).

The initial dose of nifekalant was 12.7 ± 6.1 mg and that of amiodarone was 179.5 ± 68.8 mg. Table 2 shows the therapeutic results of the antiarrhythmic drugs. Among the 14 patients in the nifekalant group, 5 achieved ROSC, 5 had continued ventricular fibrillation, and 4 had pulseless electrical activity (PEA) after the initial dose. Among the 11 patients in the amiodarone group, 4 achieved ROSC, 2 patients had continued ventricular fibrillation, 3 patients had PEA, and 2 patients had asystole after the initial dose. The rate of ROSC was 35.7 % (5/14) in the nifekalant group and 36.3 % (4/11) in the amiodarone group. The rate of survival to discharge was 28.6 % (4/14) in the nifekalant group and 18.2 % (2/11) in the amiodarone group. These differences were not significant. Two patients in the nifekalant group and no patients in the amiodarone group survived without brain damage (GOS 5).

The time from the initiation of class III antiarrhythmic drug administration to ROSC was 6.0 ± 6.6 min for nifekalant (n = 5) and 20.3 ± 10.0 min for amiodarone (n = 4); this was a significant difference (P < 0.05).

The number of shocks administered after drug administration until the termination of ventricular fibrillation was 1.6 ± 1.1 in the nifekalant group (n = 9) and 1.8 ± 1.4 in the amiodarone group (n = 9); this difference was not significant.

Four patients who had continued ventricular fibrillation after class III antiarrhythmic drug administration were

Table 2 Therapeutic results of patients with out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation treated with nifekalant or amiodarone

| Dose of antiarrhythmic drug (mg)       | Nifekalant group (n = 14) | Amiodarone group (n = 11) | P value |
|---------------------------------------|---------------------------|---------------------------|---------|
| Nifekalant                            | 12.7 ± 6.1                | 179.5 ± 68.8              |         |
| Amiodarone                            |                           |                           |         |
| Therapeutic results of antiarrhythmic drug (%) |                         |                           |         |
| ROSC and admission to ICU             | 35.7 % (5/14)             | 36.3 % (4/11)             | 0.97    |
| VF                                    | 35.7 % (5/14)             | 18.2 % (2/11)             | 0.33    |
| PEA                                   | 28.6 % (4/14)             | 27.3 % (3/11)             | 0.94    |
| Asystole                              | 0.0 % (0/14)              | 18.2 % (2/11)             | 0.10    |
| Number of DC shocks after antiarrhythmic drug use (times) (excluded patients who continued VF) | 1.6 ± 1.1 (n = 9) | 1.8 ± 1.4 (n = 9) | 0.71    |
| Time interval (min)                   |                           |                           |         |
| Antiarrhythmic drug use–ROSC          | 6.0 ± 6.6 (n = 5)         | 20.3 ± 10.0 (n = 4)       | 0.04*   |
| Survival to discharge (%)             | 28.6 % (4/14)             | 18.2 % (2/11)             | 0.89    |
| Discharge with no brain damage (GOS 5)| 14.3 % (2/14)             | 0.0 % (0/11)              | 0.19    |
| Discharge with vegetative state (GOS 2)| 14.3 % (2/14)             | 18.2 % (2/11)             | 0.79    |

Values are given as mean ± SD

DC direct current, ECLS extracorporeal life support, GOS Glasgow outcome scale, ICU intensive care unit, PEA pulseless electrical activity, ROSC return of spontaneous circulation, SD standard deviation, VF ventricular fibrillation

* Statistically significant at P < 0.05
treated with ECLS. The mean time from hospital arrival to the start of ECLS was 62.3 ± 43.3 min.

Discussion

The present study evaluates the different clinical properties of nifekalant and amiodarone for resuscitation of shock-resistant ventricular fibrillation. We compared the efficacy of nifekalant and amiodarone for out-of-hospital shock-resistant ventricular fibrillation. There were no significant differences in the rates of ROSC or survival to discharge between the two drugs, but nifekalant achieved faster ROSC than amiodarone. Because early ROSC is one of the most important factors for minimizing brain damage in cardiopulmonary arrest patients [19, 20], nifekalant has the potential to be superior to amiodarone for resuscitation of shock-resistant ventricular fibrillation. In this study, two patients in the nifekalant group and no cases in the amiodarone group returned to normal life without brain damage (GOS 5).

To the best of our knowledge, there are only two previous studies directly comparing the efficacy of nifekalant versus amiodarone for the treatment of ventricular fibrillation: one is a human study reported by Amino et al. [21] and the other is an animal model of cardiac arrest reported by Ji et al. [22].

The study by Amino et al. [21] did not show significant differences in the success rate of defibrillation or the rate of survival to discharge between nifekalant and amiodarone in patients with out-of-hospital cardiopulmonary arrest caused by shock-resistant ventricular fibrillation. They did, however, find that it took longer from amiodarone administration to defibrillation success (33 ± 22.8 min) than from nifekalant administration to defibrillation success (10 ± 10.0 min). This finding is consistent with the results of the present study, which found that nifekalant achieved faster ROSC after shock-resistant ventricular fibrillation compared with amiodarone. Our results show a slightly shorter interval from drug administration to ROSC for both nifekalant (6.0 ± 6.6 min) and amiodarone (20.3 ± 10.0 min) compared with the study by Amino et al., possibly because of differing CPR protocols. We performed CPR according to the 2005 CoSTR by ILCOR, with a protocol of one shock followed by 2 min of chest compressions [17], and Amino et al. performed CPR according to their original method, with a protocol of one shock followed by 5 min of chest compressions. The 2010 CoSTR [23] also has a protocol of one shock followed by 2 min of chest compressions. We think that the shock should be delivered quickly after antiarrhythmic drug administration to achieve ROSC, even in patients who initially have shock-resistant ventricular fibrillation.

Ji et al. [22] reported on the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest from ventricular fibrillation. The rates of ROSC and 24 h survival were comparable between nifekalant and amiodarone. Their results indicated that the efficacy of nifekalant for resuscitation resulting from ventricular fibrillation was not inferior to amiodarone. Interestingly, the coronary perfusion pressure was significantly lower in the amiodarone group than in the nifekalant group at 30 min after successful resuscitation. Although it is difficult to evaluate hemodynamic parameters such as coronary perfusion pressure during and immediately after CPR in humans, differences in coronary perfusion pressure with the use of different antiarrhythmic drugs may influence the recovery time from cardiac arrest to ROSC.

Although amiodarone is used for treating fatal ventricular tachyarrhythmias, it is known that it occasionally causes hypotension and bradycardia [4, 24]. Amiodarone has vasodilatory and negative inotropic qualities resulting from its sodium and calcium channel-blocking effects. Amiodarone also blocks α- and β-receptors. Vasodilation and negative inotropic activity are thought to be undesirable for resuscitation. On the other hand, nifekalant is a pure potassium channel blocker, with no negative inotropic activity and almost no influence on hemodynamic state [12]. Because vasodilation and negative inotropic activity are thought to be undesirable for resuscitation, nifekalant seems to have some advantage for resuscitation from a pharmacological aspect.

Different pharmacodynamics between nifekalant and amiodarone could affect the time to achieve ROSC. Nifekalant has a rapid action and clearance with a short half-life; the elimination half-life of nifekalant is 1.53–2.07 h in healthy subjects [25, 26]. On the other hand, a long serum half-life (>14 days) was observed for amiodarone [27]. Because the effect of amiodarone continues much longer than that of nifekalant, amiodarone is still blocking sodium and calcium channels strongly even if ventricular fibrillation is terminated after a DC shock.

The defibrillation threshold is an important factor in the success of resuscitation when treating shock-resistant ventricular fibrillation. Nifekalant decreases the defibrillation threshold of ventricular fibrillation [28] but amiodarone does not [29, 30]. Although nifekalant and amiodarone have different effects on the defibrillation threshold, our clinical data showed that the defibrillation success rate (the rate of ROSC) was the same for both. There was also no difference between the groups in the number of shocks from the time of drug administration to the termination of ventricular fibrillation (nifekalant, 1.6 ± 1.1, versus amiodarone, 1.8 ± 1.4), but nifekalant did achieve faster ROSC than did amiodarone. As a shock was delivered every 2 min if needed according to the 2005...
CoSTR protocol, these results indicate that both nifekalant and amiodarone terminate ventricular fibrillation on average after one or two shocks following drug administration, but amiodarone causes a longer period of asystole or PEA before ROSC than nifekalant.

The main reason for the difference between nifekalant and amiodarone in the time from drug administration to ROSC is the different effects they have, theoretically, on sodium and calcium channels. Nifekalant is a pure potassium channel blocker and has no effect on sodium or calcium channels, but amiodarone is a multichannel blocker, including potassium, sodium, and calcium channel-blocking effects. Amiodarone strongly suppresses the sinus node pacemaker function by blocking sodium and calcium channels. Even if ventricular fibrillation is terminated after a DC shock, it might be easy to induce asystole or PEA after amiodarone because the sinus node is suppressed. Negative inotropic activity by amiodarone prolongs the time to ROSC. Amiodarone also decreases systemic vascular resistance by blocking calcium channels. Low left ventricular output and dilatation of resistance vessels causes low coronary perfusion pressure. Because of the long serum half-life of amiodarone, the effect of amiodarone continues for a long time.

There are some limitations to this study. This is a single-center retrospective study with a small number of patients, and the doses of nifekalant and amiodarone varied between patients. A large prospective study is needed to determine whether nifekalant or amiodarone is superior for resuscitation of shock-resistant ventricular fibrillation. The SOS-KANTO study group is planning to start a comparison of nifekalant versus amiodarone in patients with out-of-hospital shock-resistant ventricular fibrillation by the CPR method according to the 2010 CoSTR [31].

In conclusion, in this small sample size study, nifekalant, compared with amiodarone, is equally effective for ROSC and survival to discharge after shock-resistant ventricular fibrillation and can achieve ROSC more quickly. Further clinical investigations are necessary to evaluate the effect of nifekalant compared with amiodarone.

Acknowledgments No one other than the authors contributed substantially to the performance of this study or to the drafting of the manuscript. The authors received no funding for this study. Some aspects of this study were presented at the 39th Congress of the Society of Critical Care Medicine, Miami, on January 9–13, 2010, and at the 31st International Symposium of Intensive Care and Emergency Medicine, Brussels, on March 22–25, 2011.

Conflict of interest No conflicts of interest to declare.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Valenzuela TD, Roe DJ, Nichol G, Clark LL, Spaiite DW, Hardman RG. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med. 2000;343:1206–9.
2. Weisfeldt ML, Siltani CM, Ornato JP, Rea T, Aufderheide TP, Davis D, Dreyer J, Hess EP, Jui J, Maloney J, Sopko G, Powell J, Nichol G, Morrison LJ, for the ROC Investigators. Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consortium population of 21 million. J Am Coll Cardiol. 2010;55:1713–20.
3. Kitamura T, Iwami T, Kawamura T, Nagao K, Tanaka H, Hiraide A. Nationwide public-access defibrillation in Japan. N Engl J Med. 2010;362:994–1004.
4. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, Hallstrom AP, Murray WA, Olsufka M, Walsh T. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871–8.
5. Deakin CD, Nolan JP, Soar J, Sunde K, Koster RW, Smith GB, Perkins GD. European Resuscitation Council Guidelines for Resuscitation 2010, Section 4. Adult advanced life support. Resuscitation. 2010;81:1305–52.
6. Neumar RW, Otto CW, Link MS, Kornick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support. 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:S729–67.
7. Katoh T, Mitamura H, Matsuda N, Takeno T, Ogawa S, Kasamuki H. Emergency treatment with nifekalant, a novel class III antiarrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation. Circ J. 2005;69:1237–43.
8. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation. 1991;84:1831–51.
9. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13–29.
10. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol. 1993;109:157–63.
11. Sen L, Cui G, Sakaguchi Y, Singh BN. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs. J Pharmacol Exp Ther. 1998;285:687–94.
12. Kondoh K, Hashimoto H, Nishiyama H, Umemura K, Ozaki T, Uematsu T, Nakashima M. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol. 1994;23:674–80.
13. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. J Am Coll Cardiol. 2002;34:684–90.
14. Tahara Y, Kimura K, Kosuge M, Ebina T, Sumita S, Hibi K, Toyama H, Kosuge T, Moriwaki Y, Suzuki N, Sugiyama M, Umemura S. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J. 2006;70:442–6.
15. Yusu S, Ikeda T, Mera H, Miyakoshi M, Miwa Y, Abe A, Tsukada T, Ishiguro H, Shimizu H, Yoshino H. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. Circ J. 2009;73:2021–8.

16. Shiga T, Tanaka K, Kato R, Amino M, Matsudo Y, Honda T, Sagara T, Takahashi A, Katoh T, Urashima M, Ogawa S, Takano T, Kasanuki H, for the Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study Investigators. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia. Resuscitation. 2010;81:47–52.

17. (2005) International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Part 1: Introduction. Resuscitation. 2005;67:181–186.

18. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480–4.

19. Komatsu T, Kinoshita K, Sakurai A, Moriya T, Yamaguchi J, Sugita A, Kogawa R, Tanjoh K. Shorter time until return of spontaneous circulation is the only independent factor for a good neurological outcome in patients with postcardiac arrest syndrome. Emerg Med J. 2013 (in press).

20. Hayakawa K, Tasaki O, Hamasaki T, Sakai T, Shiozaki T, Nakagawa Y, Ogura H, Kuwagata Y, Kajino K, Iwami T, Nishiuichi T, Hayashi Y, Hiraide A, Sugimoto H, Shimazu T. Prognostic indicators and outcome prediction model for patients with return of spontaneous circulation from cardiopulmonary arrest: the Utstein Osaka project. Resuscitation. 2011;82:874–80.

21. Amino M, Yoshioka K, Opthof T, Morita S, Uemura S, Tamura K, Fukushima T, Higami S, Otuka H, Akeda K, Shima M, Fujibayashi D, Hashida T, Inokuchi S, Kodama I, Tanabe T. Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. J Cardiovasc Pharmacol. 2010;55:391–8.

22. Ji XF, Li CS, Wang S, Yang L, Cong LH. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. Resuscitation. 2010;81:1031–6.

23. Nolan JP, Hazinski MF, Billi JE, Boettiger BW, Bossaert L, de Caen AR, Deakin CD, Drajer S, Eigle B, Hickey RW, Jacobs I, Kleinman ME, Klocek W, Koster RW, Lim SH, Mancini ME, Montgomery WH, Morley PT, Morrison LJ, Nadkarni VM, O’Connor RE, Okada K, Perlman JM, Sayre MR, Shuster M, Soar J, Sunde K, Travers AH, Wyllie J, Zideman D. Part 1: Executive summary. 2010 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation. 2010;81(suppl 1):e1–25.

24. Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med. 1997;127:294–303.

25. Yasuda S, Sawano H, Hazui H, Ukai I, Yokoyama H, Ohashi J, Sase K, Kada A, Nonogi H, on behalf of the J-PULSE Investigators. Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride. Circ J. 2010;74:2308–13.

26. Oyabe A, Sano H. Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug (in Japanese, English abstract). Nihon Yakurigaku Zasshi (Folia Pharmacol Jpn). 2002;119:103–9.

27. Shiga T, Tanaka T, Irie S, Hagiwara N, Kajino K. Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. Heart Vessels. 2011;26:274–81.

28. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol. 1997;29:688–92.

29. Huang J, Skinner JL, Rogers JM, Smith WM, Holman WL, Ideker RE. The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. J Am Coll Cardiol. 2002;40:375–83.

30. Tsagalou EP, Anastasiou-Nana MI, Charitos CE, Siafakas CX, Drakos SG, Italianis A, Terrovitis JV, Mavrikakis EM, Doufas A, Nanas JN. Time course of fibrillation and defibrillation thresholds after an intravenous bolus of amiodarone—an experimental study. Resuscitation. 2004;61:83–9.

31. Nagao K. Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm. Circ J. 2010;74:2285–7.